Literature DB >> 15087691

A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection.

Virender K Sharma1, Colin W Howden.   

Abstract

OBJECTIVE: Our aim was to assess current perceptions and practices of primary care physicians in the United States concerning Helicobacter pylori infection.
METHODS: We mailed a structured questionnaire to approximately 2500 primary care physicians chosen at random from a national database. We asked about personal and practice demographics and practices relating to testing for and treating H. pylori infection.
RESULTS: We received 424 responses from 2349 questionnaires (18%). Only 3% each had used either the C- or C-urea breath test; 5% had used the stool antigen test; 92% and 91% recommended testing-and 90% and 82% treatment-for H. pylori in patients with active duodenal and gastric ulcer, respectively. However, only 64% would test for and only 59% would treat H. pylori infection in a patient with past history of duodenal ulcer. Almost half would test patients with gastroesophageal reflux disease being started or maintained on a proton pump inhibitor. The most frequent treatment regimens used were combinations of a proton pump inhibitor, clarithromycin, and either amoxicillin or metronidazole. Most respondents had inaccurate information on antibiotic resistance rates for H. pylori. In the absence of symptoms, 26% would personally undergo testing for H. pylori; 30% would be treated if infected.
CONCLUSIONS: Primary care physicians usually test for and treat H. pylori infection in patients with active ulcer, but fail to do so in patients with a prior history of ulcer. Some test for H. pylori in gastroesophageal reflux disease patients. Most use efficacious treatment regimens, but have inaccurate information on resistance rates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087691     DOI: 10.1097/00004836-200404000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

1.  Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance.

Authors:  Colin W Howden; William D Chey; Nimish B Vakil
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

2.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

3.  Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.

Authors:  R Urgesi; G Pelecca; R Cianci; A Masini; C Zampaletta; M E Riccioni; R Faggiani
Journal:  Can J Gastroenterol       Date:  2011-06       Impact factor: 3.522

Review 4.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.

Authors:  Vikram Kate; Raja Kalayarasan; Nilakantan Ananthakrishnan
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Discrepancies between primary physician practice and treatment guidelines for Helicobacter pylori infection in Korea.

Authors:  Byeong Gwan Kim; Ji Won Kim; Ji Bong Jeong; Young Jin Jung; Kook Lae Lee; Young Soo Park; Jin Huk Hwang; Jin Uk Kim; Na Young Kim; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

6.  Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers.

Authors:  B M R Spiegel; M Farid; M G H van Oijen; L Laine; C W Howden; E Esrailian
Journal:  Aliment Pharmacol Ther       Date:  2009-01-15       Impact factor: 8.171

7.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

8.  Helicobacter pylori vacA arrangement and related diseases: a retrospective study over a period of 15 years.

Authors:  Vincenzo De Francesco; Marcella Margiotta; Angelo Zullo; Cesare Hassan; Floriana Giorgio; Mariangela Zotti; Giuseppe Stoppino; Alessia Bastianelli; Francesco Diterlizzi; Giovanna Verderosa; Sergio Morini; Carmine Panella; Enzo Ierardi
Journal:  Dig Dis Sci       Date:  2008-07-03       Impact factor: 3.199

Review 9.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

10.  Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario.

Authors:  Nelson F Eng; Gustavo Ybazeta; Katrina Chapman; Nya L Fraleigh; Rebecca Letto; Eleonora Altman; Francisco Diaz-Mitoma
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.